| Similar Articles |
|---|
 |
Bio-IT World
September 2006
John Russell |
Predicting the Future of Systems Biology Buoyed by promising results from a recent collaboration with Pfizer on drug-induced vascular injury, Keith Elliston, CEO of modeling and biosimulation specialist Genstruct, offers a candid view of industry's flirtation with systems biology and the future prospects for the field.   |
Bio-IT World
February 2006
John Russell |
Marvelous Models of Biological Systems Here are highlights from a roundtable discussion with researchers representing academia and pharmaceuticals, as well as executives from modeling technology providers on whether or not Pharma is ready to bet on computational modeling of biological systems. |
Bio-IT World
September 2006
John Russell |
Informatics Cornucopia Predictive Informatics, the hopeful title of a session at last month's Drug Discovery Technology & Development World Congress, remains an enticing but mostly elusive goal. Asked what systems biology would look in five years and what will constitute success, panelists offered the following. |
Bio-IT World
April 2006
John Russell |
Pfizer's Pursuit of Technology Can this $50-billion-plus, 115,000-employee behemoth succeed where other pharma giants have failed and successfully institutionalize the effort to find and develop critical new technology? Should it even try? |
Bio-IT World
March 8, 2005
John Russell |
Entelos' Lofty Aspirations This is an interesting period for systems biology's wing of predictive biology companies. The label's luster is fading, but buoyed by pharma's growing interest, they are trying to figure out how to grow. |
Bio-IT World
June 17, 2004
John Russell |
Systems Biology - Now Leaving on Track 1 Entelos, a leader in predictive biosimulation, partners with pharmaceutical and biotech organizations worldwide to develop effective new treatments for disease. Michael French, chief business officer at Entelos, explains what powers the systems biology engine. |
Bio-IT World
November 12, 2002
Michael Goldman |
A Virtual Pharmacopeia Computational modeling of disease pathways, organs --- even patients --- could transform drug discovery. Does salvation exist in silico? |
Bio-IT World
Dec 2006/Jan 2007
John Russell |
Novartis' Answer to Harry Potter Imagine a magic wand able to instantly materialize novel, safe, and effective drugs. No such device exists, of course, but Novartis has a distant cousin of sorts: the UltraLink is an immensely powerful text-mining tool and knowledge management platform. |
Bio-IT World
May 19, 2004
John Russell |
Seeing the Forest and the Trees A tiny clearing in the fog of systems biology. |
Bio-IT World
October 2006
John Russell |
GNS Charts "Unknown" Biology Gene Network Sciences' CEO and colleagues now think they have the right tool to mine the treasure trove of unknown biology hidden in the wealth of accumulating omic data. |
Bio-IT World
Dec 2006/Jan 2007 |
Resolute in the New Year Industry leaders in areas from pharmacogenetics to cheminformatics found 2006 to be a year of important steps forward, but looked with even more anticipation to 2007: Allen D. Roses, SVP, Pharmacogenetics GlaxoSmithKline... etc. |
Bio-IT World
March 2007
John Russell |
In Search of Spring Tired of winter? Here are some signs of spring for systems biology acceptance and a preview of Cambridge Healthtech's June conference, Applying Systems Biology, to whet your appetite for summer: 1. FDA Survey... etc. |
Bio-IT World
September 2005
John Russell |
Labor Pains and Gains Labor Day is the starting gun for the bio-science industry's race through the next year. Here are some up-and-coming items to watch: Transparency... Systems Biology... Crawford and McClellan... |
Bio-IT World
Jul/Aug 2006
John Russell |
MathWorks Launches a 'Systems Biology' Tool The maker of the popular MATLAB programming environment recently launched a modeling product, SimBiology, aimed at systems biology and synthetic biology markets. |
Bio-IT World
September 2006
Kevin Davies |
Pfizer's Global Survey of Pharmacological Space The pharma blends knowledge, computational chemistry and research informatics to build a unified database. Gathering all the data in one place offered greater control for indexing and data retrieval and management, enabling Pfizer scientists to perform global mapping. |
The Motley Fool
October 1, 2008
Brian Orelli |
Is Pfizer the Mystery Bidder? A few signals that Pfizer might be the one bidding on ImClone. |
Fast Company
June 2004
Bill Breen |
The Thrill of Defeat Want to know how to motivate people to take on tough odds? Ask the folks in Pfizer's labs, where managing failure is a fine art and superhuman persistence an everyday habit. |
Bio-IT World
December 15, 2003
Zachary Zimmerman |
Learning the Language of Systems Biology Geneticist par excellence David Botstein talks about his philosophy, science, his mission for integrative science, and what he deems a success for systems biology. |
Bio-IT World
September 2006
Nat Goodman |
Getting a Handle on Systems Biology Systems biology is squarely an experimental field that eats, drinks, and breathes data. To do systems biology, you need an experimental system that is amenable to large-scale experimentation. |
The Motley Fool
June 15, 2010
Brian Orelli |
Pfizer Focuses, Investors Should Cheer The culling of the pipeline continues at Pfizer. While that's bad news for partners that signed on with the company or with Wyeth before the merger it's a good move for Pfizer. |
CIO
October 15, 2001
Stephanie Overby |
Drug Companies on speed The marriage of IT and medical research may be just what traditional pharmaceutical companies need to survive in an increasingly competitive field. Learn how IT is bringing the pharmaceutical industry into the information age... |
The Motley Fool
January 28, 2010
Brian Orelli |
Only the Strong Survive at Pfizer The culling of the pipeline isn't as bad as it sounds. |
The Motley Fool
November 21, 2007
Brian Lawler |
Pfizer Finds an Old Friend Pfizer announces its purchase of partner Coley Pharmaceutical, securing Coley's novel technology for targeting toll-like receptors. |
Bio-IT World
March 17, 2004 |
Pharma's Genomic Harvest How Pfizer plans to meet its goal of 20 new drug applications by 2006. |
Bio-IT World
February 10, 2003
Salvatore Salamone |
Made in Manhattan A talk with the new head of the Computational Biology Center at Memorial Sloan-Kettering. |
Bio-IT World
June 12, 2002
Beth Schachter |
Informatics Moves to the Head of the Class The race is on to increase the quantity and quality of bio-IT training programs as government and academia bet the need will be great. Will the job market back up that bet? |
Bio-IT World
August 2005
John Russell |
Pfizer's Model of Success Pfizer Global Research & Development began using sophisticated modeling technology and collaboration software to speed its race to a go-no-go decision on a cholesterol-lowering drug project. Killing the project sooner saved up to $2.8 million in costs and six months in delay. |
Bio-IT World
February 2007 |
Bio*IT World's Coming Attractions 2007 Bio-IT World Conference & Expo preview -- Meet the Keynotes... Oracle Users... Systems are Go... Candid Camera... A Vital IT Alliance... Next Generation Informatics... etc. |
The Motley Fool
June 11, 2008
Brian Lawler |
Dueling Fools: Pfizer Bear Is Pfizer ready for a comeback? The bearish opinion is that shares may be down, but the bleeding still isn't over. |
The Motley Fool
September 11, 2007
Brian Lawler |
Looking Forward at Pfizer With generic competition on the way for Pfizer's top drug, Lipitor, the company stepped up to the podium at the Bear Stearns Healthcare Conference this week to let investors know its plans. |
The Motley Fool
August 17, 2011
Ilan Moscovitz |
Pfizer Is Cheaper Than You Think Let's examine Pfizer alongside some of its peers for additional context. |
The Motley Fool
December 9, 2009
Brian Orelli |
Welcome to Club Biogeneric, Pfizer! The megadrugmaker jumps on the biogeneric bandwagon. |
Chemistry World
September 13, 2012
Andy Merritt |
Chemical biology comes of age Historically strongest in the US, chemical biology has become increasingly important worldwide, but for many years researchers at the chemistry -- biology interface have struggled to establish their discipline |
The Motley Fool
October 20, 2006
Brian Lawler |
Pfizer Keeps Fighting If Pfizer's management can succeed on its cost-savings initiatives and maintain the high single digits of earnings-per-share growth that it expects in 2007-2008, then Pfizer may make a good investment for those willing to wait for the company's new drugs to bring back higher growth. |
The Motley Fool
April 5, 2005
Stephen D. Simpson |
Pfizer Pfaces Its Pfuture Analysts and investors seem happy with Pfizer's long-term strategy. Should they be? |
The Motley Fool
January 14, 2008
Brian Lawler |
Worst Stock for 2008: Pfizer This analyst thinks that Pfizer is a good company, but a bad stock for 2008. |
The Motley Fool
June 20, 2011
Luke Timmerman |
Pfizer's Idea to Fix the Drug Development Crisis, Which Probably Won't Work (But Just Might) In a worst-case scenario, Pfizer flushes a few hundred million dollars down the tubes. What's the best-case scenario? |
CIO
October 28, 2011
Kim S. Nash |
Pfizer's Future Depends on IT Transformation With its business model ailing, this pharmaceutical giant tries a new IT formula, including a loyalty discount card, mobile applications aimed at consumers, and a cloud-based tablet CRM system for physicians. |
Pharmaceutical Executive
March 1, 2009
Walter Armstrong |
Attack of the Monster Merger Just when you thought it was safe to go back into M&A, the mega merger returns. What's right about Pfizer-Wyeth, and what's scary. |
Bio-IT World
Dec 2006/Jan 2007
Allison Proffitt |
'An Unfortunate Storm': Tripos CEO Discusses Company Future Tripos announced that it has successfully sold its Discovery Informatics business to Vector Capital. Despite the company's difficulties, including a collapsed share price, president and CEO John McAllister is upbeat about the company's future. |
IndustryWeek
May 1, 2006
Jonathan Katz |
St. Louis: Gateway For New Medicines Considering the St. Louis region a strategic location for developing new drugs, Pfizer Inc. has consolidated its R&D operations there for greater collaboration. |
The Motley Fool
February 22, 2007
Brian Lawler |
Dueling Fools: Pfizer Bear It's been a blue chip for years, but that doesn't mean it will stay that way forever. It's inconceivable for Pfizer's market capitalization to be valued at $188 billion four years from now, when its revenues could be 40% lower than they are today. |
The Motley Fool
January 23, 2007
Ryan Fuhrmann |
Back to the Future at Pfizer Pfizer just provided guidance for the next couple of years. The news shows that the company is willing to shake things up, but investors should remain skeptical until tangible benefits occur. |
